Reactions 1704, p283 - 2 Jun 2018 ALT increased: case report In a study of seven patients, one patient [age and sex not stated] was described who developed ALT rise following treatment with nivolumab and pembrolizumab [routes, dosgaes, durations of treatments to reaction onset not stated]. The patient, who had cancer [unspecified], received treatment with nivolumab and pembrolizumab. The patient also had concurrent HCV infection. Subsequently, the patient developed rise in ALT level (grade II). Therefore, the patient received treatment for HCV infection and consequently the ALT level returned to baseline. Author comment: "Our results indicate that patients with metastatic melanoma and NSCLC can be safely treated with anti-PD1 immunotherapy in the context of HBV/HCV infection. Only one patient demonstrated an ALT rise greater than CTCAE Grade 1 severity". Kothapalli A, et al. Safety and efficacy of anti-PD1 therapy for metastatic melanoma and non-small cell lung cancer in patients with concurrent viral hepatitis. Australasian Journal of Dermatology 59 (Suppl. 1): 79, May 2018. Available from: URL: http://doi.org/10.1111/ajd.17_12815 [abstract] - Australia 803323376 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera